Medivation Inc (NASDAQ:MDVN) and Astellas Pharma announced plans to commence a Phase III clinical trial to investigate the use of enzalutamide for the treatment …
Medivation Inc (NASDAQ:MDVN) announced that the talazoparib-containing arm of the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And …
In light of recent 1Q earning results from pharmaceutical companies Endo International plc – Ordinary Shares (NASDAQ:ENDP), and Medivation Inc (NASDAQ:MDVN), Barclay’s analysts …
Medivation Inc (NASDAQ:MDVN) announced that its Board of Directors, after consultation with its financial and legal advisors, unanimously determined that the unsolicited proposal from …
Medivation Inc (NASDAQ:MDVN) confirmed that it has received an unsolicited, non-binding proposal from Sanofi to acquire all outstanding shares of Medivation common stock for $52.50 …
Medivation Inc (NASDAQ:MDVN) announced that Phase I data from its investigational agent talazoparib, a highly-potent PARP inhibitor, was presented at the American Association …
Medivation Inc (NASDAQ:MDVN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …
Healthcare analysts are weighing in on prostate cancer drug maker Medivation Inc (NASDAQ:MDVN) and biopharmaceutical company Genocea Biosciences Inc (NASDAQ:GNCA). While one analyst provides an acquisition scenario analysis …
Medivation Inc (NASDAQ:MDVN) announced that the U.S.
Medivation Inc (NASDAQ:MDVN) reported its financial results for the fourth quarter and year ended December 31, 2015. “We are delighted with our substantial …
